Leukocare AG, a biotechnology company specialized in the field of biopharmaceutical formulation development, announced in August 2021 that Dr. Cornelius Pompe, in former position at Amgen Research, joined the company as Vice President R&D. In this role, he succeeded Dr. Sabine Hauck, who has been appointed as Senior Vice President Corporate Development at Leukocare.

Michael Scholl, Chief Executive Officer at Leukocare, said, “I am delighted to welcome Cornelius to the management team. His extensive industry experience will help us to further strengthen our R&D expertise and to serve our clients in the best possible way.

Dr. Cornelius Pompe brings more than 15 years of experience in early and late-stage biopharmaceutical development. Before joining Leukocare, Cornelius served as Head of Drug Product Development, Early Operations Lead and Member of the Process Development Senior Leadership Team at Amgen Research in Munich, Germany. Prior to his roles at Amgen, he held several positions in the area of drug product development at LFB Group, Courtaboeuf, France, and at Coriolis Pharma, Martinsried, Germany. Cornelius holds a PhD in Pharmaceutical Technology from Ludwig Maximilians University Munich, Germany.

Dr. Cornelius Pompe, Vice President R&D at Leukocare, commented, “I am very happy to join Leukocare´s management team. When I learned about Leukocare’s approach to combine bioinformatics and deep learning with best-in-class analytics to redefine formulation development, I was excited. In my past roles, I have experienced many challenges with formulations of complex biologics and I see a tremendous value in Leukocare’s enhanced way of making use of the full potential of a drug substance. I am convinced that Leukocare is the right place to bring in my industry experience. I am looking forward to closely collaborate with this dedicated team of experts.”